ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL2007641
CHEMBL2007641
Compound Name PERTUZUMAB
ChEMBL Synonyms RHUMAB 2C4 | RG-1273 | RHUMAB-2C4 | OmniTarg Perjeta | PERTUZUMAB
Max Phase 4 (Approved)
Trade Names OmniTarg Perjeta

Sources

  • British National Formulary
  • Clinical Candidates
  • Manually Added Drugs
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL2007641 compound icon
Drug Type:Antibody Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Receptor protein-tyrosine kinase erbB-2 inhibitor Receptor protein-tyrosine kinase erbB-2 DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
BREAST NEOPLASMSD001943EFO:0003869BREAST NEOPLASM4ClinicalTrials
NEOPLASMSD009369EFO:0000311CANCER4ClinicalTrials
CARCINOMA, NON-SMALL-CELL LUNGD002289EFO:0003060NON-SMALL CELL LUNG CARCINOMA2ClinicalTrials
BREAST NEOPLASMSD001943EFO:0000305BREAST CARCINOMA4ClinicalTrials
DailyMed
NEOPLASMSD009369EFO:0000616NEOPLASM4ClinicalTrials
ATC
PROSTATIC NEOPLASMSD011471EFO:0001663PROSTATE CARCINOMA2ClinicalTrials

Clinical Data

ClinicalTrials.gov PERTUZUMAB
The Cochrane Collaboration PERTUZUMAB

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XC - Monoclonal antibodies
L01XC13 - pertuzumab

ChemSpider ChemSpider Identifier not yet assigned
DailyMed pertuzumab
Wikipedia Pertuzumab
spacer
spacer